Drug Information

Drug General Information
Drug ID
D0T4SL
Former ID
DNC005820
Drug Name
9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527769]
Structure
Download
2D MOL

3D MOL
Formula
C18H16N2O
Canonical SMILES
CC1=C2C(=C(C3=C1C=CN=C3)C)C4=C(N2)C=CC(=C4)OC
InChI
1S/C18H16N2O/c1-10-15-9-19-7-6-13(15)11(2)18-17(10)14-8-12(21-3)4-5-16(14)20-18/h4-9,20H,1-3H3
InChIKey
BKRMCDAOAQWNTG-UHFFFAOYSA-N
PubChem Compound ID
72512
Target and Pathway
Target(s) Mast/stem cell growth factor receptor Target Info Inhibitor [527769]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
Hematopoietic cell lineage
Melanogenesis
Pathways in cancer
Acute myeloid leukemia
Central carbon metabolism in cancer
NetPath Pathway IL3 Signaling Pathway
IL4 Signaling Pathway
KitReceptor Signaling Pathway
Pathway Interaction Database C-MYB transcription factor network
Signaling events mediated by Stem cell factor receptor (c-Kit)
Reactome PIP3 activates AKT signaling
Regulation of KIT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascade
WikiPathways Kit receptor signaling pathway
Differentiation Pathway
Signaling by SCF-KIT
PIP3 activates AKT signaling
Cardiac Progenitor Differentiation
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
References
Ref 527769J Med Chem. 2005 Oct 6;48(20):6194-201.Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
Ref 527769J Med Chem. 2005 Oct 6;48(20):6194-201.Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.